0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover674.98%IV-292.67%PremiumDec 20, 2024Expiry Date5.59Intrinsic Value100Multiplier27DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.4310Delta0.1128Gamma0.30Leverage Ratio-0.0252Theta-0.0036Rho-0.13Eff Leverage0.0020Vega
Rafael Holdings Stock Discussion
🟢 Recently Announced:
⇒ $Organon & Co (OGN.US)$ to acquire Dermavant
⇒ $Rafael Holdings (RFL.US)$ to acquire Cyclo Tx
⇒Crown Lab to acquire $Revance Therapeutics (RVNC.US)$
⇒ $Recursion Pharmaceuticals (RXRX.US)$ merger with Exscientia
🔴 Recently Closed:
⇒ $Johnson & Johnson (JNJ.US)$ acquired V-Wave
⇒ Pharmacosmos acquired $GTHX
What companies will be next? 🤔
Cyclo Therapeutics' TransportNPC(TM) Phase 3 clinical trial for Trappsol(R) Cyclo(TM) for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, I...
No comment yet